Viking Therapeutics, Inc. VKTX

35.56 (1.19) (3.24%) as of 25 Sep
Market cap
$4.3B
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Net Income
(534.80) (472.33) (359.64) (237.39)

+8 more TTM periods

Depreciation & Amortization
(5.48) (7.01) (8.80) (11.06)
Non Cash Items (Other)
37.42 39.75 40.77 37.92
Accounts Payable Change
63.52 59.48 43.44 4.16
Change in payables and accrued liability
14.47 27.77 6.17 (3.73)
Change in other assets and liabilities
6.43 12.01 (0.63) (14.47)
Operating Cash Flow
(418.44) (340.33) (278.68) (224.58)
Short Term Investments Change (Net)
399.26 332.33 341.39 272.36
Investing cash flow
399.26 332.33 341.39 272.36
Equity Repurchase (Common, Net)
37.30 14.22 2.49 2.34
Other financial activities
— — 73.92 —
Financing cash flow
111.25 88.17 76.44 2.34
Exchange Rate Adjustment
0.02 0.01 (0.01) (0.09)
Change in Cash
92.07 80.18 139.13 50.03
Beginning Cash
165.81 165.81 26.68 26.68
Ending Cash
257.89 245.99 165.81 76.71
Stock Based Compensation
37.39 39.81 40.82 37.90
Dividends Paid (Common)
0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
84.42 99.26 48.98 (14.04)
Investments Change (Net)
399.26 332.33 341.39 272.36
Issuance/Purchase of Shares
37.30 14.22 2.49 2.34

Fold the line items

In millions of $ except per-share values · columns are period end dates